It was a great pleasure to meet with Dr Christina Muzny (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss the findings from the recent Phase III clinical study that has led to the approval of secnidazole for the treatment of trichomoniasis and bacterial vaginosis.
- What are the unmet needs in the treatment of trichomoniasis and bacterial vaginosis? (0:18)
- What is the mechanism of action of secnidazole? (2:49)
- Could you tell us a little about the Phase III clinical study that has led to the approval of secnidazole? (3:55)
- What were the efficacy and safety findings of the study? (5:17)
- What will be the impact of this approval on clinical practice? (6:18)
Disclosures: Christina Muzny has received research grants to my UAB from, NIH, Lupin, Gilead, Abbott; is on the Speaker Board for Cepheid; is on Scientific Advisory Boards for PhagoMed, Roche, Abbott; receives speaker honoraria -from Cepheid, Roche, BD, Abbott; and is involved in the development of educational presentations for Jesperson & Associates.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Bacterial and Fungal Infections
John Walton Sanders, IDWeek 2021: Unmet Needs in the Treatment of Candida Osteoarticular Infections
It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the unmet needs in the treatment of Candida osteoarticular infections. The abstract entitled: ‘Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)’ […]
John Walton Sanders, IDWeek 2021: Subset Analysis of Phase 3 FURI Study, Investigating Candida Bone and Joint Infections
It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the a subset analysis of the Phase 3 FURI study investigating the outcomes of patients with Candida bone and joint infections when treated with ibrexafungerp. The abstract entitled: ‘Outcomes of […]
Esmita Charani: Tackling Global Antimicrobial Resistance
We caught up with touchINFECTIOUS DISEASES expert faculty member, Dr Esmita Charani (Imperial College London, London, UK), to discuss her recent research into the future research priorities to optimise antimicrobial use in humans, and what research gaps still remain. Useful resources: Research roadmap for optimising the use of antibiotics in humans Publication available here: Charani […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!